Eli Lilly Raises 2026 Revenue Guidance 2.5%, EPS by 5.8% on 47% Sales Growth
AMGN•Eli Lilly boosted its full-year 2026 revenue guidance by 2.5% and EPS forecast by 5.8%, lifting the stock 20.3% since the April update. The firm's revenue surged 47.4% over the past year versus a 37.9% three-year average, offset by a low-to-mid-teens pricing headwind and steady pipeline progress.
1. Guidance and Stock Performance
Management raised full-year 2026 revenue guidance by 2.5% and EPS forecasts by 5.8% on April 30, sparking a 20.3% stock rally in the weeks that followed.
2. Revenue Growth Acceleration
The company’s trailing twelve-month revenue climbed 47.4%, outpacing its three-year average growth rate of 37.9%, indicating accelerating market demand for its products.
3. Pricing Pressures
U.S. net pricing is projected to decline in the low-to-mid-teens for the full year, a tradeoff for volume gains after a 10% price drop last quarter excluding a one-time adjustment.
4. Pipeline Highlights
Positive developments on oncology candidate Jaypirca and dermatology asset EBGLYSS complement flagship drugs Mounjaro and Zepbound, underscoring multiple growth drivers ahead.
